Literature DB >> 26260651

Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma.

Thorsten Derlin1, Ulrich Baumann2, Frank M Bengel3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26260651     DOI： 10.1007/s00259-015-3161-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

2.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Authors:  S S Chang; D S O'Keefe; D J Bacich; V E Reuter; W D Heston; P B Gaudin
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

3.  Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.

Authors:  Matthias Eiber; Tobias Maurer; Michael Souvatzoglou; Ambros J Beer; Alexander Ruffani; Bernhard Haller; Frank-Philipp Graner; Hubert Kübler; Uwe Haberkorn; Michael Eisenhut; Hans-Jürgen Wester; Jürgen E Gschwend; Markus Schwaiger
Journal:  J Nucl Med       Date:  2015-03-19       Impact factor: 10.057

4.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

5.  Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Authors:  Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper
Journal:  J Nucl Med       Date:  2012-12       Impact factor: 10.057
  5 in total
  2 in total

Review 1.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 2.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.